Loading stock…

Cochlear Limited (COH) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Cochlear Limited

COHMarket cap $5.89BPrice $89.6

Country🇦🇺Australia

SectorHealthcare

IndustryHealthcare Equipment

Makes implantable devices that let deaf and severely hearing-impaired people hear, controlling over half the global cochlear implant market. Its devices restore a sense doctors once considered permanently unfixable, turning silence into sound for over 700,000 people worldwide.

In Bastion Portfolios?

52W Return-51%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+8%6

Revenue Forecast

Rev CAGR (1y)+2%3

Rev CAGR (3y)+4%4

Rev CAGR (5y)+5%4

Earnings Forecast

EPS Growth Y+1+133%10

EPS Growth Y+2+9%6

EPS Growth Y+3+13%7

Quality

Margins

EBIT Margin18%7

Net Income Margin6%4

Free Cash Flow Margin13%7

Debt

Net Debt/EBITDA0.09

Efficiency

ROE8%4

ROA5%6

Earnings Stability44

GEAR+WEAK25

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)253

P/E Ratio (Forward 3y)203

P/BV4.83

EV Multiples

EV/EBITDA Fwd154

EV/EBIT Fwd194

Yield

Free Cash Flow Yield3.6%5

Dividend Yieldna–

Momentum

Short term

1 month return-3%6

3 month return+6%8

YTD return-49%1

Mid term

Price vs 52wHigh44%1

1 year return-53%1

Long term

3 year return-47%1

5 year return-36%2

Risk Shield

Price Risk

Beta0.95

Volatility64%2

Free Cash Flow

Free Cash Flow Margin13%7

Free Cash Flow Yield3.6%5

Quality

ROCE20%9

Earnings Stability44

Net Debt/EBITDA0.09

02Growth

Is it actually growing, and how fast?

COHCochlear

Revenue FY26$1.6B

GROWTH RATING↗

AVERAGE38 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+4%4

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+133%10

EPS growth, FY28E+9%6

EPS growth, FY29E+13%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 13%/yr vs revenue 4%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 38% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

COHCochlear

Total return Current−13.8%

Price return Current−25.0%

MOMENTUM RATING↗

VERY WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+6%8

YTD return-49%1

MID & LONG-TERM▾SCORE

% of 52-week high44%1

1-year return-53%1

3-year return-47%1

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+6%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-47% over three years and -36% over five), behind 80% of the market.

It's down 53% over the past year, now 56% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-49%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Cochlear Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

COHCochlear

Revenue FY26$1.6B

GROWTH RATING↗

AVERAGE38 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+4%4

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+133%10

EPS growth, FY28E+9%6

EPS growth, FY29E+13%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 13%/yr vs revenue 4%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 38% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

COHCochlear

Total return Current−13.8%

Price return Current−25.0%

MOMENTUM RATING↗

VERY WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+6%8

YTD return-49%1

MID & LONG-TERM▾SCORE

% of 52-week high44%1

1-year return-53%1

3-year return-47%1

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+6%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-47% over three years and -36% over five), behind 80% of the market.

It's down 53% over the past year, now 56% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-49%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Cochlear Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community